United Therapeutics Co. (NASDAQ:UTHR) Director Christopher Causey Sells 510 Shares

United Therapeutics Co. (NASDAQ:UTHR) Director Christopher Causey sold 510 shares of the business’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $376.63, for a total value of $192,081.30. Following the sale, the director now owns 3,675 shares of the company’s stock, valued at $1,384,115.25. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

United Therapeutics Trading Up 0.7 %

UTHR stock traded up $2.78 during trading on Monday, hitting $376.80. The company had a trading volume of 328,484 shares, compared to its average volume of 466,008. The company has a fifty day moving average price of $355.40 and a two-hundred day moving average price of $317.82. The company has a market cap of $16.82 billion, a P/E ratio of 16.55, a P/E/G ratio of 1.35 and a beta of 0.56. United Therapeutics Co. has a fifty-two week low of $208.62 and a fifty-two week high of $379.51.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. The company had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business’s revenue was up 22.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $5.38 earnings per share. On average, analysts expect that United Therapeutics Co. will post 24.85 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Bank of America decreased their target price on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a report on Thursday, August 1st. The Goldman Sachs Group upped their target price on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research report on Friday. Argus upped their target price on United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday. TD Cowen upped their target price on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Finally, UBS Group upped their price target on United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a research report on Monday, July 8th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $370.86.

Institutional Investors Weigh In On United Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in UTHR. ClariVest Asset Management LLC increased its holdings in shares of United Therapeutics by 120.0% in the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 42 shares in the last quarter. V Square Quantitative Management LLC bought a new stake in United Therapeutics in the second quarter valued at approximately $30,000. Innealta Capital LLC bought a new stake in United Therapeutics in the second quarter valued at approximately $33,000. USA Financial Formulas bought a new stake in United Therapeutics in the third quarter valued at approximately $33,000. Finally, Capital Performance Advisors LLP bought a new stake in United Therapeutics in the third quarter valued at approximately $82,000. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.